Nothing dangerous is expected
[DOI] [PMC free article] [PubMed] [Google Scholar] 40.Belloc S, Hazout A, Zini A, Merviel P, Cabry R, Chahine H, et al
doi:10.1016/s0368-1319(68)80089-4
Discovery Timeline 1980searly 1990s: Melanocortin analog development First, researchers developed increasingly potent and stable -MSH analogs to study pigmentation and melanocortin receptor biology
Alternatives to GLP-1 medications while breastfeeding If youre holding off on a GLP-1 while nursing, there are still supportive, realistic ways to protect your metabolic health during the postpartum period (period after giving birth)
In the PIONEER 1 trial, oral semaglutide 14 mg reduced HbA1c by approximately 1.2-1.4% from baseline, with significant proportions of patients achieving HbA1c targets below 7%